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ABSTRACT 
Objective: Development and validation of reverse phase high performance liquid chromatographic (RP-HPLC) method with UV-Vis detector for in 
vitro determination of lynestrenol with levonorgestrel as an internal standard in human plasma.  
Methods: The RP-HPLC method was developed using a C18 Sunfire© waters column with a mobile phase of acetonitrile containing 0.1% formic acid 
in water (60:40), respectively, at a flow rate of 1.0 ml/min and was detected at a wavelength of 204 nm. Lynestrenol and levonorgestrel were 
extracted from human plasma using pentane with protein precipitation method. 
Results: The RP-HPLC method was able to selectively quantify lynestrenol in blood plasma on 40 ng/ml. The assay exhibited a linear dynamic range 
40-1000 ng/ml for lynestrenol with retention time 4.0 second, and the coefficient correlation (r) was 0.9994. Accuracy (% diff) of this method was-
10.81% to 8.72% with precision (CV) being 3.84% to 8.12%, and complete recovery was established to be 98.27% to 106.49%. The method was 
sensitive, selective, and has simple sample preparation extraction lynestrenol in plasma with pentane was successfully developed.  
Conclusion: The method can be used to analyze lynestrenol in blood plasma, with a simple pretreatment procedure using pentane.  
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INTRODUCTION 
Lynestrenol is a derivative of progesterone, which is an endogenous 
steroid hormone produced by the ovaries, and cortex. Lynestrenol is 
used for women contraception and as a treatment for menstrual 
bleeding, maturation of the follicles in the ovaries and ovulation. For 
menstruation delay, doses of lynestrenol is 1 mg/day, which plasma 
levels exceeded 0.7 ng/ml [1, 2]. 
Lynestrenol in the digestive tract is absorbed rapidly with 
bioavailability, about 64%. Lynestrenol is metabolized in the liver 
through norethindrone metabolite about 98%. Conversion of 
lynestrenol to norethindrone through hydroxylation reaction on C-3 
and 3β hydroxyl-lynestrenol with CYP2CP, CYP2C19, and CYP3A4 
enzymes [3, 4].  
Determination of the concentration of drugs in plasma through 
bioavailability studies that can measure the speed and amount of 
drugs absorbed by the body is a study of drug products that 
illustrates the effectiveness of drug preparations [5]. 
High-performance liquid chromatography (HPLC) methods are 
commonly used in analyzing drug concentrations in plasma. HPLC 
can separate substances that interfere with analysis and determine 
the smallest concentration of drug in plasma [6, 7]. 
Guidelines for validation of bioanalysis methods generally refer to 
the Food and Drug Administration and also the European Medicines 
Agency. However, research that refers to EMEA is still rarely done 
because of relatively new in the revision of the bioanalysis validation 
method [8, 9]. 
In this research, the liquid-liquid extraction method was performed on 
human blood plasma obtained from the Indonesian Red Cross. Liquid-
liquid extraction using pentane and bioanalysis validation of the 
extraction method used refers to European Medicines Agency 
guidelines (EMEA). High-Performance Liquid Chromatography used 
for analysis with a mobile phase of acetonitrile containing 0.1% format 
in water (60:40), a flow rate of 1.0 ml/min in the reverse phase of 
column C18 (150 mm), and detected at wavelength 204 nm [10]. 
MATERIALS AND METHODS 
Instrumentation  
High-Performance Liquid Chromatography (Shimadzu, Japan) 
equipped with a UV-Vis SPD 10A detector. LC-Solution data 
processor and integrator CBM 102; microsyringe 5 µl (Hamilton, 
Nevada); column C-18 (Waters, SunfireTM 5 μm; 150 x 4.6 mm); 
ultracentrifuge (Corning); vortex mixer (VM-300 Germany Industrial 
Corporation, USA), sonicator (Branson 3200, USA).  
Chemical 
Lynestrenol (Indian Penal Code, Pirumadara), Levonorgestrel 
(Sigma Aldrich, Singapore), Acetonitrile Pro HPLC (Merck), Methanol 
Pro HPLC (Merck), Formic Acid (Merck), Pentane (Merck), 
Potassium Dihydrogen Phosphate (Merck), Sodium Hydroxide 
(Merck), anticoagulant Citrate (Indonesian Red Cross), human blood 
(Indonesian Red Cross). 
Chromatography system 
This study was implementing HPLC with a UV-Vis detector, column 
C18 with length 150 x 4.6 mm, detected at 204.0 nm wavelength, 
using a mobile phase of acetonitrile containing 0.1% Formic acid in 
water (60:40) with a flow velocity of 1.0 ml/min, injection volume 
was 20 μL and used levonorgestrel as the internal standard.  
Preparation of standard solution 
10.0 mg lynestrenol was dissolved in methanol in a 10 ml volumetric 
flask to obtain 1.0 mg/ml (1000 ppm) concentration. Levonorgestrel 
standard 10.0 mg was dissolved in the mobile phase to obtain 1.0 
mg/ml (1000 ppm). The dilution was conducted to obtain solutions 
in certain concentrations. 
Plasma sample preparations 
The liquid-liquid extraction method was conducted by adding 25 μl 
levonorgestrel 100 μg/ml to 500 μl plasma which containing 50 μg/ml 
lynestrenol and 1 ml buffer phosphate 7.4 in microtube and vortexed 
for 30 seconds. Next, 1 ml pentane was added, and the mixtures were 
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vortexed for 3 min and then centrifuged at 10.000 rpm for 10 min on 
25 °C. The organic phase was transferred to another tube and repeated 
three times and evaporated with Nitrogen gas (N2), then the residue 
was reconstituted in 100 μl methanol. Afterward, 20.0 μl aliquot was 
injected into the HPLC system. 
Validation of lynestrenol analysis in plasma 
Referring to EMEA Guideline for Bioanalytical Method Validation 
2011, before validation running, system suitability must be apparent. 
Validation of the lynestrenol analytical method in plasma was 
conducted with selectivity carry over, LLOQ, linear calibration curve, 
accuracy, precision, and recovery, dilution integrity, and stability [10]. 
RESULTS AND DISCUSSION 
The plasma concentration of lynestrenol is relatively low and shows 
significant inter-individual variations in uptake, storage, and 
metabolism. The analysis of lynestrenol in human plasma has been 
reported with detection limits lower than 0.7 ng/ml by HPLC. 
Therefore, a more sensitive analytical method is needed to monitor 
the precise concentrations in plasma during pharmacokinetic 
studies. The study was performed with low lynestrenol dosing. 
A different method for extraction of lynestrenol in plasma is 
described using C18 solid-phase extraction. Extraction of lynestrenol 
of this research in plasma with various organic solvents. Extraction 
with pentane gave high recoveries regardless of the concentration of 
lynestrenol; therefore, pentane was chosen for the extraction. 
Based on the mobile phase was used in this validation is acetonitrile, 
containing 0.1% formic acid in water (60:40). The addition of formic 
acid on the mobile phase had the desirable effect of maintaining a 
reasonably high capacity factor (k) resolution (Rs) and tailing 
factors (Tf) for the analyte. A concentration of 1 mmol formic acid in 
the mobile phase was large enough to achieve the reproducible 
elongated retention time (tr) for the analyte [11]. 
System suitability 
According to the European Medicines Agency in 2011, system 
suitability tests are an integral part of any liquid chromatographic 
method. The parameters were performed on lynestrenol and 
levonorgestrel, including retention time (tr), areas (µV. s), 
resolutions (Rs), the number of theoretical plates (N), HETP, and 
tailing factor (Tf). All these parameters were found to be satisfactory 
and within the reported acceptance listed in the reference. As shown 
in table 1, the tailing factor was<2, acceptable retention time along 
with good resolution is indicative of good efficiency and selectivity 
of the method for separation of lynestrenol and levonorgestrel as an 
internal standard. 
  
Table 1: HPLC system suitability parameters for determination of lynestrenol and levonorgestrel 
Analytes Retention time (tr) Areas (µV. s) resolutions (Rs) Tailing factors (Tf) HETP Theoretical plates (N) 
Lynestrenol 4.018 11334 13.241 0.782 0.00034 21324.5 
Levonorgestrel 5.560 8498 9.242 0.837 0.00024 2435.4 
 
Lower limit of quantification (LLOQ) 
The LLOQ value is related to the sensitivity of a method, smaller the 
LLOQ value indicating of more sensitive method that can measure 
the lowest concentration of analytes from the plasma matrix. In 
bioanalysis, the LLOQ value must cover a minimum of 1/20 of the 
maximum concentration (C max) of the analyte in the plasma. The 
LLOQ which meet the requirements giving±20% of %diff (EMEA, 
2011). Based on the analysis of lynestrenol in plasma, table 2 shows 
that the LLOQ value of 40.0 ng/ml was applied, while that was 
applied at 20.0ng/ml (half concentration), the value of % diff would 
rise to above the requirements. 
  
Table 2: LLOQ value of lynestrenol 
Real concentration (ng/ml) Measured concentration±SD (ng/ml) % CV %Diff 
40 42.596±2.493 5.853 -3.445 to 11.786 
20 14.545±2.918 20.061 -34.969 to-1.178 
 
Selectivity 
Selectivity test was conducted in the blank plasma and LLOQ 
concentrations, 40.0 ng/ml using six different plasmas (A to F). Each 
sample was analyzed and evaluated separately to determine 
interference. The results show, the selectivity study on the blank did 
not show any interference or impurities during the analysis of the 
analytes and the internal standard. The results show that the value 
of the % interference is 0.063-11.658%. Selectivity data of 
lynestrenol are shown in table 3. 
  
Table 3: Selectivity value of lynestrenol 
Real concentration (ng/ml) Plasma Measured concentration±SD (ng/ml) % CV %Diff 
 A 38.877±0.217   
 B 42.254±1.823   
40  C 41.365±2.002 6.607 0.063-11.658 
 D 38.909±0.836   
 E 39.961±1.027   
 F 35,336±1.242   
 
Calibration curve and linearity 
The calibration curve consists of plasma blanks (plasma without 
analytes and internal standards), zero samples (plasma with internal 
standards) and non-zero plasma (plasma with analytes and internal 
standards) as many as 7 concentrations, namely 40.0 ng/ml, 80.0 
ng/ml, 120.0 ng/ml, 250.0 ng/ml, 500.0 ng/ml, 750.0 ng/ml, 1000.0 
ng/ml. The value of % diff from the results of the measurement 
concentration should not deviate more than±15%, except for LLOQ 
not to deviate more than±20%. Based on statistical calculations, a 
linear regression equation is produced, namely y = 0.023x+0.252 
with a correlation coefficient (r) = 0.9994 where x is the sample 
concentration, and y is PAR (peak area ratio) between the response 
area of the analyte with the internal standard as shown in fig. 1. The 
calibration curve was linear with the correlation coefficient 
(r>0.9991) in the concentration range from 40.0 to 1000.0 ng/ml. 
LLOQ concentration of lynestrenol was 60.0 ng/ml, with the CV 
value of 3.69% and % diff between-3.445 to 11.786%. 
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Fig. 1: Calibration curve of lynestrenol 
 
Carry-over 
Carry-over must be minimized during the method development 
process. During the validation process, carry-over was assessed by 
injecting blanks, after previously being injected with a high 
concentration sample or calibration standard on ULOQ (1000.0 
ng/ml) of five replicas and analyzed sequentially. Carry-over on the 
blank should not be more than 20% of LLOQ and 5% for internal 
standards [11]. Carry-over value after injection of high 
concentrations of lynestrenol range from 2.88% to 6.09% of the 
LLOQ response, while the standard %carry-over ranged from 
0.98%to 3.35%. Based on research, carry over study results did not 
exceed the requirements, so it could be concluded during the 
analysis process that there was no meaningful participation between 
injections. The chromatogram of blank plasma and chromatogram of 
ULOQ shown in fig. 2. 
 
 
Fig. 2: A representative chromatogram of blank plasma (left) and a representative chromatogram of ULOQ (left), with retention time (tR) 
of lynestrenol 3.911 and levonorgestrel 5.543 (right) 
 
Accuracy and precision 
In this study, intra-day and inter-day (3 d) accuracy and precision 
were tested. Lynestrenol in plasma was made at LLOQ concentrations 
of 40.0 ng/ml, QCL low concentrations of 120.0 ng/ml, QCM moderate 
concentrations of 500.0 ng/ml, and QCH high concentrations of 750.0 
ng/ml. Based on the results of the study, the accuracy and precision 
test lynestrenol values obtained%diff in the four concentrations range 
from-13.68% to-13.81% and the coefficient of variation in LLOQ 
concentrations, low, medium and high respectively was 5.62%, 7.62%, 
8.53%, and 8.25%. The accuracy and precision test results have met 
the requirements of%diff, and CV values do not exceed±15% for low, 
medium, and high concentrations; and at LLOQ concentrations do not 
exceed±20% shown in table 4. 
 

















40.0 40.89±2.09 -4.44 to 6.61 4.48 40.68±3.60 -3.51 to 8,76 8.86 
120.0 125.44±6.68 -2.18 to 7.49 3.84 116.44±4.74 -9.61 to 6.71 4.07 
500.0 468.31±24.22 -5.42 to 8.72 7.17 518.57±30.04 -1.28 to 7.90 8.53 
750.0 726.90±38.78 -10.81 to 1.77 8.12 785.72±48.15 -4.24 to 9.18 6.12 
 
Recovery 
Recovery study was also carried out in the research, with the 
concentrations used were low, medium, and high concentrations. An 
absolute recovery study was obtained by comparing the measured 
concentration with the actual concentration. The results obtained for 
low, medium, and high concentrations range from 102.41%-107.94%, 
96.41%-106.22%, and 86.32%-104.80%, respectively. The coefficient 
of variation for low, medium, and high concentration analytes were 
2.31%, 4.71%, and 4.55%, respectively. Next, the extraction efficiency 
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study was calculating by %recovery. The recovery test (%recovery) 
provides information about the extraction efficiency of an analytical 
method under conditions that can change. The results do not have to 
be 100% but should be consistent, precise, and reproducible. The % 
recovery is obtained by comparing the analyte response that was 
added after the plasma blank was extracted with the response of the 
analyte that was extracted. Based on the results of the study, shown in 
table 3, the coefficient of variation for low, medium, and high 
concentration analytes in a row were 2,81%, 3.49%, and 8.82%. 
Recovery data of lynestrenol are shown in table 5. 
 
Table 5: Recovery values of analit and internal standard 
Actual cons. 
(ng/ml) 
Analit Internal standard 
% Recovery±SD (ng/ml) CV (%) % Recovery±SD (ng/ml) CV (%) 
120.0 106.49±2.95 2.31 102.82±5.73 2.81 
500.0 99.81±23.51 4.71 98.91±4.82 3.49 
750.0 98.27±33.57 4.55 105.82±6.49 8.82 
 
Dilution integrity 
The effect of dilution was explored to validate that human plasma 
samples more significant than the highest concentration of the 
calibration range could be diluted with blank plasma and quantified 
without losing reproducibility. This parameter serves to assess the 
dilution process carried out during the bioanalysis process to be 
accurate, precise, and reliable. The test results obtained must be 
within the established criteria, namely±15%. The dilution integrity 
test must include the dilution used in the study sample [12]. The 
accuracy and precision values of the dilution still fulfill the strict and 
precise criteria so that the dilution process carried out during the 
bioanalysis process can be trusted.  
Stability 
The storage stability of lynestrenol was investigated to establish the 
probability of degradation occurred during long term storage in each 
plasma. Stability was analyzed using QCL and QCH samples, each with 
three replications. For the short-term stability, samples were stored at 
room temperature, and the stability was observed in 0, 6, and 24 h. 
The obtained results showed that lynestrenol samples were stable to 
be stored in the room temperature minimum of 24 h, shown in table 6. 
The obtained results showed %diff for the short-term stability of 
lynestrenol was from-1.95% to 1.99%, and %diff for lynestrenol short 
stability was from-1.85 to-1.64%. The results showed that the 
lynestrenol solutions and levonorgestrel solutions were stable when 
stored at room temperature for a minimum of 24 h.  
For long-term stability, samples were stored in the freezer in-4 °C 
for 7 and 14 d. The obtained results showed that lynestrenol 
samples were stable to be stored in the freezer in-4 °C minimum 14 
d, shown in table 7. For long-term stability, the obtained results of 
%diff lynestrenol were between-2.06% to-1.96%, and the %diff of 
lynestrenol solutions were between-1.81% to-1.57% for 14 d in4 °C. 
Therefore, lynestrenol and levonorgestrel stock solutions could be 
used for 14 d.  
The freeze-thaw stability test was also conducted. Lynestrenol in 
plasma was found stable after freeze-thaw test in three cycles 
minimum. The results are shown in Table 8. The short-term stability 
of standard solutions of lynestrenol and the internal standard were 
tested at room temperature for 24 h. The long-term stability of the 
standard solutions was stored in 4 °C for 1, 10, and 18 d. 
 
Table 6: Lynestrenol short-term stability in the plasma in room temperature 
Time QCL 120.0 ng/ml QCH 750.0 ng/ml 
Measurable Concentration±SD (ng/ml) CV (%) Measurable concentration ±SD (ng/ml) CV (%) 
0 hour 126.26±6.20 4.91 740.72±38.32 5.17 
6 h 128.07±10.26 8.01 740.63±61.86 8.35 
24 h 129.76±15.96 12.3 749.58±34.63 84.62 
 
Table 7: Lynestrenol long-term stability in the plasma in-4 °C 
Day 
 
QCL 120.0 ng/ml QCH 750.0 ng/ml 
Measurable Concentration±SD (ng/ml) CV (%) Measurable Concentration±SD (ng/ml) CV (%) 
0 126.95±4.82 3.80 724.15±41.70 5.76 
8 120.46±4.63 3.84 710.63±36.62 5.15 
18 123.67±4.82 3.94 729.89±56.17 7.69 
 
Table 8: Lynestrenol freeze-thaw stability in the plasma 
Cycles 
 
QCL 120.0 ng/ml QCH 750.0 ng/ml 
Measurable consentration±SD (ng/ml) CV (%) Measurable consentration±SD (ng/ml) CV (%) 
0  132.69±1.68 1.27 734.28±15.88 2.16 
3 128.07±2.21 1.72 788.47±30.12 3.82 
 
CONCLUSION 
The method has been validated and can be used to analyze 
lynestrenol in blood plasma. The simplicity of the assay, with a 
simple pretreatment procedure using pentane, makes it an attractive 
procedure for the high-throughput bioanalysis of lynestrenol.  
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